Alector, Inc. (ALEC) Stock: Price, Forecast & Analyst Target
Alector, Inc. (ALEC) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $2.30 (-10.51%), as of the Nov 19, 2026 trading session; market cap $342M.
Educational signal · not a buy or sell recommendation · How to read this
Alector, Inc. · ALEC · NASDAQ
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. Their pipeline includes treatments for Alzheimer's, Parkinson's, frontotemporal dementia, and amyotrophic lateral sclerosis.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Alector (ALEC)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and elite growth. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $3M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 1 of the last 4 reports
- Altman Z -0.21 · Piotroski F 5
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 37 | Weak | |
| 31 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 32 | Weak | |
| 32 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.30 | |
| Change on the day | -10.51% | |
| Market capitalisation | $342M | — |
| Price / earnings (trailing) | 7.31 | |
| Shares traded on the day | 1.63M |
Price & events
Other perspectives
Council score for Alector (ALEC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Alector (ALEC), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Alector, Inc. (ALEC) is listed on NASDAQ. It employs 103 people. In Q3 FY2025 it reported revenue of $3M and net income of -$35M. The market values it at $342M.
What do the latest results show for Alector (ALEC)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $3M. Against analyst estimates the company has EPS beat 1 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $3M | -$35M | -$0.34 (diluted) |
| Q4 FY2025 | $6M | -$37M | -$0.34 (diluted) |
| Q1 FY2026 | $1M | -$23M | -$0.21 (diluted) |
| Q2 FY2026 | $3M | -$23M | -$0.21 (diluted) |
What are the financial strengths and risks for Alector (ALEC)?
Short answer
The MoonshotScore pillars rate business quality, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z -0.21 · Piotroski F 5. Trailing ratios: ROE 47.5% · ROA 9.5% · current ratio 4.10.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -0.21 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Alector (ALEC)?
Short answer · as of
Current published price targets run low $1.50 · high $7.00 · consensus $3.83 · median $3.00 against a quoted price of $2.30 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2025) was filed Nov 6, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Alector compare with its peers?
Short answer
Alector's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1382.75 Nov 18, 2026 | $1.23T | 98 5-pillar Nov 18, 2026 | |
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $536.45 Nov 18, 2026 | $136B | 90 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Alector (ALEC) — this page | $2.30 | $342M | 32 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $1.50 – $7.00
- Consensus target
- $3.83
- Median target
- $3.00
Consensus record · Captured .
Measured against a quoted price of $2.30 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 14, 2026
- Transactions
- 55
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 5
- Other transactions
- 50
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ALEC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ALEC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Alector (ALEC)?
Alector Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ALEC research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ALEC?
ALEC carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases.
Is ALEC a good stock to buy?
Stock Expert AI does not rate ALEC buy, sell or hold. Alector, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ALEC stock price today?
The last price recorded for Alector, Inc. (ALEC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ALEC price target?
The analyst consensus price target for Alector, Inc. (ALEC), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about ALEC stock?
Analyst coverage of Alector (ALEC) is mixed, reflecting the inherent risks and potential rewards of clinical-stage biotechnology companies. Some analysts highlight the potential of Alector's immuno-neurology approach and its promising pipeline of therapies. Others express concerns about the company's high cash burn rate and reliance on clinical trial success.
What are the key factors to evaluate for ALEC?
Alector, Inc. (ALEC) holds a MoonshotScore in the low range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. The collaboration with GlaxoSmithKline is a prime example of this strategy. Not financial advice.
How frequently does ALEC data refresh on this page?
ALEC's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ALEC's recent stock price performance?
Alector, Inc. (ALEC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel immuno-neurology approach. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALEC overvalued or undervalued right now?
The trailing P/E of Alector, Inc. (ALEC) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 15 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com